Compare SBSI & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SBSI | VALN |
|---|---|---|
| Founded | 1960 | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 920.2M | 820.0M |
| IPO Year | N/A | 2021 |
| Metric | SBSI | VALN |
|---|---|---|
| Price | $30.58 | $8.84 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $33.50 | $15.75 |
| AVG Volume (30 Days) | ★ 153.5K | 23.1K |
| Earning Date | 10-24-2025 | 11-20-2025 |
| Dividend Yield | ★ 4.72% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.30 | N/A |
| Revenue | ★ $236,346,000.00 | $211,089,992.00 |
| Revenue This Year | $11.41 | $5.08 |
| Revenue Next Year | $5.33 | $12.53 |
| P/E Ratio | $13.27 | ★ N/A |
| Revenue Growth | N/A | ★ 13.48 |
| 52 Week Low | $25.85 | $3.62 |
| 52 Week High | $35.99 | $12.25 |
| Indicator | SBSI | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 66.92 | 48.70 |
| Support Level | $30.11 | $8.56 |
| Resistance Level | $30.90 | $9.62 |
| Average True Range (ATR) | 0.64 | 0.27 |
| MACD | 0.18 | 0.04 |
| Stochastic Oscillator | 90.91 | 43.26 |
Southside Bancshares Inc is a bank holding company. Through its subsidiary, the Southside Bank, it operates as a financial institution offering various financial services to individuals, businesses, municipal entities, and nonprofit organizations. These services include consumer and commercial loans, deposit accounts, wealth management and trust services, brokerage services, and safe deposit services. The company's primary market areas are East Texas, Southeast Texas, and the greater Dallas-Fort Worth, Austin, and Houston, Texas.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.